A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy.
To utilize Bifidobacterium longum (B. longum) as a safe and stable delivery system for endostatin in cancer gene therapy, we constructed pBV22210 vector combining a chloramphenicol-resistance gene (Cm(r)) from pBCSK(+) plasmid, a cryptic plasmid pMB1 from B. longum strain with pBV222. Endostatin was cloned directly downstream of an N terminal His6-tag sequence in the pBV22210, so that the endostatin protein expressed in B. longum could be purified with Ni-binding resin. The results indicated that the plasmid electroporated into B. longum was maintained stably in the absence of selective antibiotics and did not significantly affect biological characteristics of B. longum. In addition, the plasmid in B. longum showed a strong inhibitory effect on the growth of mouse solid liver tumor in vivo. These results suggested that this new plasmid may be a stable vector in B. longum for transporting anti-cancer genes in cancer gene therapy.
Xu
Y-F
YF
Department of Biological Science and Technology and State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, 22 Hankou Road, Nanjing University, Nanjing 210093, China.
Zhu
L-P
LP
Hu
B
B
Fu
G-F
GF
Zhang
H-Y
HY
Wang
J-J
JJ
Xu
G-X
GX
D000818:Animals; D001483:Base Sequence; D001644:Bifidobacterium / Q000235:genetics*; D017931:DNA Primers; D004351:Drug Resistance; D018274:Electroporation; D043169:Endostatins / Q000008:administration & dosage*; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy*; D010957:Plasmids
D017931:DNA Primers; D043169:Endostatins